BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14555332)

  • 1. Value of prostate-specific antigen in the staging of Taiwanese patients with newly diagnosed prostate cancer.
    Meng E; Sun GH; Wu ST; Chuang FP; Lee SS; Yu DS; Yen CY; Chen HI; Chang SY
    Arch Androl; 2003; 49(6):471-4. PubMed ID: 14555332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
    Stock RG; Stone NN; Ianuzzi C; Unger P
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer.
    Rees MA; Resnick MI; Oesterling JE
    Urol Clin North Am; 1997 May; 24(2):379-88. PubMed ID: 9126235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The criteria for avoiding unnecessary computerized tomography and bone scan in staging patients with newly diagnosed prostate cancer: retrospective study of patients at Matsusaka Chuo General Hospital].
    Matsumura Y; Otani T; Yoneda T; Matsumoto Y; Maruyama Y; Fujimoto K; Hirao Y
    Nihon Hinyokika Gakkai Zasshi; 2007 Sep; 98(6):764-9. PubMed ID: 17929458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
    Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
    Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.
    Narayan P; Fournier G; Gajendran V; Leidich R; Lo R; Wolf JS; Jacob G; Nicolaisen G; Palmer K; Freiha F
    Urology; 1994 Oct; 44(4):519-24. PubMed ID: 7524237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
    Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
    J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.
    Arenas LF; Füllhase C; Boemans P; Fichtner J
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients.
    Lee N; Newhouse JH; Olsson CA; Benson MC; Petrylak DP; Schiff PB; Bagiella E; Malyszko B; Ennis RD
    Urology; 1999 Sep; 54(3):490-4. PubMed ID: 10475360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital.
    O'Sullivan JM; Norman AR; Cook GJ; Fisher C; Dearnaley DP
    BJU Int; 2003 Nov; 92(7):685-9. PubMed ID: 14616446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The staging pelvic lymphadenectomy: implications as an adjunctive procedure for clinically localized prostate cancer.
    Alagiri M; Colton MD; Seidmon EJ; Greenberg RE; Hanno PM
    Br J Urol; 1997 Aug; 80(2):243-6. PubMed ID: 9284196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.